Chronic GVHD (cGVHD) frequently affects the oral cavity. The purpose of this study was to estimate the efficacy of combined topical dexamethasone (DEX) and tacrolimus (TAC) solutions in the management of oral cGVHD. The records of 14 patients with oral cGVHD treated with combined topical DEX/TAC were reviewed retrospectively. Pre-to-post treatment changes in subjective and objective measures were evaluated at a median follow-up of 60 days. Serum TAC levels were examined. Marginal objective improvement was detected at followup. The median pre-to-post treatment differences were 0.5 (range, À1 to 1) for erythema score, and 0.5 (range, 0 to 2) for lichenoid score, (P ¼ 0.06, 0.07 and 0.02, respectively). Subjective improvement was noted in three of four measures at the follow-up visit. The median differences in pain, sensitivity and dryness scores were 1 (range À1 to 6), 1 (range À3 to 5) and 2.5 (range, À5 to 5), respectively (0-10 scale, Po0.05). Four patients (37%) showed increased serum TAC levels; however, all remained within therapeutic range. In conclusion, combined topical DEX/ TAC therapy appears to be effective in reducing symptoms attributable to oral cGVHD. Our data has shown minimal evidence of systemic TAC absorption.
Introduction
Chronic GVHD (cGVHD) is a common and serious complication following allogeneic hematopoietic cell transplantation (HCT). cGVHD develops due to alloreactive donor T-lymphocytes that initiate inflammation, apoptosis and subsequent target tissue dysfunction. 1, 2 Multiple organs may be affected, with the most common being the skin, gastrointestinal tract and liver. 3 Despite prophylaxis regimens and available immunosuppressive and immunomodulatory therapies, cGVHD remains the leading cause of non-relapse treatment-related mortality in those surviving beyond 2 years after allogeneic HCT. 2, [4] [5] [6] The oral cavity is involved in approximately 80% of patients with cGVHD, with variable mucosal findings that include lichenoid changes, erythema, ulceration and superficial mucoceles. [5] [6] [7] [8] Mouth pain, and in particular sensitivity or intolerance to normally tolerated foods and drinks, is a common complaint. 1 In addition, the major and minor salivary glands are frequently affected, with symptoms of xerostomia and dysphagia further contributing to limited oral intake and impaired quality of life. 9, 10 Despite systemic therapy with corticosteroids and steroid-sparing immunomodulatory agents, effective management of oral cGVHD often requires intensive localized topical treatment. 11 Both topical corticosteroids and calcineurin inhibitors have shown evidence of efficacy in the form of ointments, gels and rinses. [12] [13] [14] Oral lesions refractory to topical immunosuppressive monotherapy may require combined therapy; however, this therapeutic approach has not been previously reported. The primary objective of this retrospective review was to describe the clinical outcomes of combined dexamethasone (DEX) and tacrolimus topical rinses in the management of patients with symptomatic oral cGVHD.
Materials and methods

Patients
A retrospective record review was conducted for patients who had undergone allogeneic HCT, and were referred to the Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA for the evaluation and management of oral cGVHD from August 2005 to March 2009. All patients who were referred for treatment were either (1) off all immunosuppressive medication, but with persistent oral cGVHD, or (2) had oral disease that was inadequately managed symptomatically despite systemic therapies. We included all patients who had clinically evident and symptomatic oral cGVHD that were treated with combined topical DEX (0.5 mg/5 ml) and tacrolimus (0.5 mg/5 ml; TAC) solutions, and had at least one follow-up visit, 49-89 days after the initial treatment, for a response assessment. None of the patients were using any additional topical or localized therapies for management of their oral cGVHD.
Response criteria
Standardized subjective and objective data were prospectively collected at the time of clinical evaluation by a single oral medicine specialist (NT). Subjective data included National Institutes of Health (NIH) staging (0-3; Table 1 ), pain (0-10), sensitivity (0-10) and dryness (0-10) scores. Objective data included scoring for lichenoid changes, erythema, ulcerations and mucoceles using the NIH total score. Serial serum TAC measurements were obtained for patients who were also being treated with concurrent systemic TAC.
Application of topical therapies
All patients were instructed to rinse with both solutions at the same time, using a total of 5.0 ml (2.5 ml DEX, 2.5 ml TAC), for 5 min before expectorating. Based on severity of symptoms, patients were allowed to rinse up to four times a day, with most rinsing 2-3 times a day (data not shown). Patients were instructed not to eat or drink for at least 15 min after applications. Tacrolimus solution was compounded according to the following formulary for 100 ml: tacrolimus powder 0.01 g, flavor 4.0 ml, Oral plus 50 ml, Oral sweet to 100 ml (America's Compounding Center, Newton, MA, USA). DEX solution (Roxane Laboratories Inc., Columbus, OH, USA), was obtained through patients' local pharmacies.
Evaluation of serum tacrolimus levels Serum TAC levels were evaluated in eleven patients who were already being treated with systemic TAC therapy and had at least one measurement before and after the administration of topical therapy (day 0). Per standard institutional monitoring, serial trough TAC serum measurements were collected routinely beginning with the initiation of systemic therapy. Systemic absorption secondary to topical therapy could not be evaluated because serum levels were not collected according to a uniform schedule and the frequency of topical dosing (including the day of serum collection) was not standardized.
Statistical analysis
The first follow-up visit (FU1) was defined as 12-49 days from the initial visit and initiation of therapy, and the second follow-up visit (FU2) was defined as 49-86 days following the initial visit. The change in subjective and objective component scores from baseline to FU1 and FU2 was calculated (difference ¼ baseline-FU1 or FU2; a positive difference is indicative of improvement) and assessed using a Wilcoxon's signed-rank exact test. Objective measures were also considered categorically as the proportion of patients who improved (lower scores at FU1 or FU2 from baseline), remained stable, or worsened (higher scores at FU1 or FU2 from baseline) and were assessed using a marginal homogeneity exact test (an extension of McNemar's test for multinomial ordered responses). P-values were considered significant at the o0.05 level. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA) and StatXact version 8.0 (Cytel Inc., Cambridge, MA, USA). This study was approved by the Dana-Farber/Harvard Cancer Center's Office for Human Research Subjects.
Results
Twenty-three patients were identified who had been referred to the Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA for the evaluation and management of oral cGVHD and had been treated with combined topical DEX and TAC solutions. Fourteen cases fulfilled the eligibility criteria and were included for analysis ( Table 2 ). All patients were evaluated during the FU2 period, and 11 (79%) were also evaluated during FU1. Serial TAC serum levels were available for 11 (79%) patients. At baseline, five patients (36%) were already being treated with single-agent topical DEX (3/5) or TAC (2/5) therapy with inadequate response. Concurrent systemic immunomodulatory therapies are summarized in Table 3 .
The median improvement in the NIH total score was 0.5 at FU2 (range À2 to 6, P ¼ 0.06), and unchanged at FU1 (range À2 to 5, P ¼ 0.41; Figure 1 ). Both erythema and lichenoid feature scores demonstrated a statistically significant improvement at FU2 (Table 4) . For erythema, 50% improved, 43% remained stable and only 7% worsened (Po0.05). Lichenoid changes similarly showed 50% improving and 50% unchanged (Po0.05). Overall the majority of objective scores remained stable at FU1 and improved at FU2 (Figure 1 and Table 4 ). Patient-reported subjective outcomes are plotted in Figure 2 . There were statistically significant improvements in median pain (1.0, range À3 to 5, Po0.05) and sensitivity (1.0, range À1 to 6, Po0.05) scores at FU2, but not FU1. There was a statistically significant improvement in the median dryness score at FU1 (2.0, range À3 to 4, Po0.05) and FU2 (2.5, range À5 to 5, Po0.05).
Serum TAC levels were evaluated in 11 patients ( Figure 3 ). All patients included in this part of the study had at least one TAC serum level read before and after the start of topical treatment within a specified time frame (À50 to þ 90 days). Over all data points, the median serum level Topical dexamethasone/tacrolimus therapy for oral cGVHD H Mawardi et al was 4.4 ng/ml (range 1.0-16.3 ng/ml; therapeutic range 5-20 ng/ml). Four patients (37%) had increased TAC serum peak levels that correlated temporally to the administration of topical therapy (cases 6, 8, 13 and 14) . Of these four patients, cases 8 and 14 had levels that were already trending upwards before the administration of topical therapy, and throughout FU2 none exceeded the upper therapeutic range limit. Case 13 had a systemic TAC dose adjustment during the serum level peak, from 0.5 to 1.0 mg.
Discussion
Chronic GVHD is a major impediment for the broader use of HCT and remains the leading cause of non-relapse treatment-related mortality. 2 Oral involvement in cGVHD is common and can have a tremendous impact on oral intake, nutrition and overall quality of life. Several localized ancillary treatment regimens have been reported in the literature including rinsing with corticosteroid-or calcineurin inhibitorcontaining solutions, steroid injections and phototherapy. 11, 15 Topical corticosteroids and tacrolimus have been reported as effective monotherapy. [12] [13] [14] 16 As cGVHD is routinely managed systemically with multiple medications with complementary mechanisms of action, it is possible that cases of oral cGVHD that are refractory to monotherapy may benefit from a combined topical approach. It was from this premise that we began treating our refractory patients with combined topical DEX/TAC therapy.
Combined DEX/TAC topical therapy resulted in improvement of objective and subjective outcomes in the majority of patients measured during this study period. Although most were on concurrent systemic therapy, most regimens were stable or tapered during the study period, strongly suggesting a direct topical effect of the combined rinses. As the NIH instruments were only recently introduced, there have been few publications with which to compare these results. 16 The overall magnitude of responses was greater at FU2 compared with FU1, suggesting that duration of therapy is likely an important factor in clinical efficacy. Concurrent systemic immunomodulatory therapies were in large part stable during the evaluation period, further supporting the efficacy of combined topical therapy. As data were evaluated retrospectively, and a standard dosing frequency was not Topical dexamethasone/tacrolimus therapy for oral cGVHD H Mawardi et al followed, the role of intensity of therapy could not be determined. Sialogogue therapy was included under monitored systemic therapy as this may have had a role in improving the dryness scores. Subjective response to combined therapy was more pronounced compared with objective criteria. Subjective measures are intended to reflect the impact of oral cGVHD on quality of life, which is typically what drives targeted therapy to the oral cavity. 17 Our data failed to show significant objective response except for lichenoid scores. One possible explanation for the non-significant change in objective scores is the retrospective design of this study and selective bias. Duration of therapy also appeared to be an important factor as greater improvement was noted at FU2 compared with FU1.
There are a number of limitations to the findings of this study. The patients included were likely to have more severe/refractory oral cGVHD compared with all patients from our center that developed oral cGVHD during the study period. Although such organ (oral cavity) specific data is not routinely collected outside of the oral medicine clinic, it is highly unlikely that there were additional patients treated with combined DEX/TAC therapy that was seen only in the oncology clinic. Follow-up visits were not scheduled according to a protocol, therefore it is feasible that responders who experienced significant improvement in symptoms with the start of combined DEX/ TAC therapy might have been less likely to return for follow-up and therefore not meet the criteria for inclusion in this study. In contrast, patients with no or minimal response might have been more likely to return and be included in a higher proportion in this study, potentially marginalizing the magnitude of the reported treatment effect. Another significant limitation is the lack of data on compliance with respect to both the frequency and duration of rinses. Prescription instructions were reviewed in detail, and at follow-up every patient was specifically asked how they were using the topical medications (frequency and duration); as the requirement and motivation for treatment was driven by patient symptoms, we have no reason to believe that these answers were not accurate, as has been discussed by others. 18 There have been several reports of the use of topical TAC for the management of oral cGVHD. 13, 14, 19 All previous reports of intraoral topical tacrolimus applications have described the use of the commercially available ointment (Protopic, Astellas Pharmaceuticals, North Deerfield, IL, USA), which is not designed for application to wet mucosal surfaces and can be very difficult to use. As oral cGVHD is often extensive, rinses, such as DEX, are often preferred, easy to use by patients and are considered a mainstay of therapy. 20 Although the compounding of TAC in an aqueous solution has been reported for oral dosing in pediatric patients, this is the first report on the use of topical TAC in a compounded rinse. 21 Although many studies have established the safety profile of topical tacrolimus in managing multiple conditions, [22] [23] [24] [25] there have been recent reports raising the concern about the development of clinically significant tacrolimus serum levels with topical use. 14, [26] [27] [28] Although the extent of TAC absorption through oral mucosa remains unclear, there is evidence for increased absorption through diseased skin. 14, [26] [27] [28] [29] [30] The mechanism behind higher absorption may be explained by impairment of the mucosal barrier in severe oral cGVHD cases. Two cases associated with intraoral topical TAC use have been reported. In one case, the TAC Topical dexamethasone/tacrolimus therapy for oral cGVHD H Mawardi et al plasma level increased from 11.6 ng/ml to 45.6 ng/ml (stable level due to systemic therapy) 2 days after starting topical ointment therapy. 28 In the second case, increased TAC plasma level was measured in a 6-year-old patient (8.6 ng/ ml) after erroneous over-dosage with topical TAC ointment. 14 Corrocher et al. 31 reported undetectable serum TAC level (o1.5 ng/ml) in 11 patients treated with 0.1% ointment for desquamative gingivitis after 4 weeks of treatment. Our data demonstrated minimal evidence of systemic TAC absorption; however, larger prospective studies are needed.
Combined topical DEX/TAC therapy appears to be effective in reducing the symptoms of oral cGVHD. Patientreported outcomes, in particular sensitivity, might be considered as more reliable measures of cGVHD disease activity compared with objective criteria. Our findings, largely support the combined topical therapy with DEX/TAC as a protocol for refractory oral cGVHD, and may be considered as firstline therapy in more severe cases. Investigations with other topical agents, alone and in combination, in the context of larger well-designed clinical trials and quality of life studies are still needed. We are currently investigating the efficacy of DEX and TAC prospectively as a single-agent topical therapy for new onset oral cGVHD (NCT00686855; www.clinicaltrials. gov). Prospective randomized studies are necessary to establish evidence-based management and monitoring guidelines for this significant and often long-term oral complication following allogeneic HCT. 
